OncLive.com路 @OncLive 路 X路路 21 hours agoScore70
Body
馃挜 Survival was improved with durvalumab plus enfortumab vedotin in patients with MIBC according to new data from the phase 3 VOLGA trial
Full details 鉃★笍: https://www.onclive.com/view/durvalumab-plus-enfortumab-vedotin-improves-survival-in-cisplatin-ineligible-mibc
#oncology #blcsm #ESMO26 @myESMO
164 views 路 0 likes 路 2 reposts 路 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: OncLive.com 路 x.com